Target Name: MIR379
NCBI ID: G494328
Review Report on MIR379 Target / Biomarker Content of Review Report on MIR379 Target / Biomarker
MIR379
Other Name(s): hsa-miR-379-5p | MIRN379 | hsa-miR-379-3p | hsa-mir-379 | mir-379 | microRNA 379 | MicroRNA 379

MIR379: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker

MIR379 (hsa-miR-379-5p) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study , and a number of studies have investigated its potential as a drug vector.

MIR379 is a microRNA (miRNA), a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation. It is expressed in a variety of tissues and cells and can interact with target genes to either enhance or suppress their expression . The five-point microRNA structure consists of a stem-loop, a loop region, and a tail region.

MIR379 has been shown to play a role in a variety of biological processes, including cell growth, apoptosis (programmed cell death), and inflammation. It has also been linked to a number of diseases, including cancer. For example, studies have shown that MIR379 is downregulated in various types of cancer, and that inhibiting its expression may be a promising strategy for cancer treatment.

One of the challenges in studying MIR379 is its difficulty in translation into a drug. While it is possible to use RNA interference (RNAi) technology to knockdown MIR379 in cells, this approach can be difficult to scale up to treat humans. Additionally, the lack of human studies available makes it difficult to determine the safety and efficacy of MIR379-based drugs.

Despite these challenges, researchers are still actively working on improving the development of MIR379-based drugs. One approach is to investigate the potential efficacy of MIR379 inhibitors in preclinical models of cancer, such as cell-based assays and animal models. Another approach is to study the effects of MIR379 inhibitors on cancer cell proliferation and metastasis.

Another promising strategy for studying MIR379 is its potential as a biomarker. By using techniques such as qRT-PCR (q reverse transcription polymerase) and western blotting, researchers have shown that MIR379 can be used as a reliable biomarker for a variety of diseases, including cancer. For example, studies have shown that MIR379 levels are downregulated in various types of cancer, and that inhibiting its expression may be a promising strategy for cancer diagnosis and treatment.

In addition to its potential as a drug target and biomarker, MIR379 has also been shown to have a number of potential therapeutic benefits. For example, studies have shown that MIR379 can act as a chaperone, helping to transport proteins to their correct destinations in the cell. Additionally, MIR379 has been shown to play a role in regulating cellular processes such as cell adhesion and migration.

Overall, MIR379 is a promising molecule for drug research and biomarker development. While there are still many challenges to be addressed, the unique structure and function of MIR379 make it an attractive target for researchers to study. As research continues, it is likely that MIR379 will emerge as a valuable tool for the treatment of a variety of diseases.

Protein Name: MicroRNA 379

The "MIR379 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR379 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286